Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Improved prediction of immune checkpoint blockade efficacy across multiple cancer types.
Chowell D, Yoo SK, Valero C, Pastore A, Krishna C, Lee M, Hoen D, Shi H, Kelly DW, Patel N, Makarov V, Ma X, Vuong L, Sabio EY, Weiss K, Kuo F, Lenz TL, Samstein RM, Riaz N, Adusumilli PS, Balachandran VP, Plitas G, Ari Hakimi A, Abdel-Wahab O, Shoushtari AN, Postow MA, Motzer RJ, Ladanyi M, Zehir A, Berger MF, Gönen M, Morris LGT, Weinhold N, Chan TA. Chowell D, et al. Among authors: weiss k. Nat Biotechnol. 2022 Apr;40(4):499-506. doi: 10.1038/s41587-021-01070-8. Epub 2021 Nov 1. Nat Biotechnol. 2022. PMID: 34725502 Free PMC article.
Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors.
Valero C, Lee M, Hoen D, Weiss K, Kelly DW, Adusumilli PS, Paik PK, Plitas G, Ladanyi M, Postow MA, Ariyan CE, Shoushtari AN, Balachandran VP, Hakimi AA, Crago AM, Long Roche KC, Smith JJ, Ganly I, Wong RJ, Patel SG, Shah JP, Lee NY, Riaz N, Wang J, Zehir A, Berger MF, Chan TA, Seshan VE, Morris LGT. Valero C, et al. Among authors: weiss k. Nat Commun. 2021 Feb 1;12(1):729. doi: 10.1038/s41467-021-20935-9. Nat Commun. 2021. PMID: 33526794 Free PMC article.
High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab.
Lee CH, DiNatale RG, Chowell D, Krishna C, Makarov V, Valero C, Vuong L, Lee M, Weiss K, Hoen D, Morris L, Reznik E, Murray S, Kotecha R, Voss MH, Carlo MI, Feldman D, Sachdev P, Adachi Y, Minoshima Y, Matsui J, Funahashi Y, Nomoto K, Hakimi AA, Motzer RJ, Chan TA. Lee CH, et al. Among authors: weiss k. Mol Cancer Res. 2021 Sep;19(9):1510-1521. doi: 10.1158/1541-7786.MCR-21-0053. Epub 2021 May 26. Mol Cancer Res. 2021. PMID: 34039647 Free PMC article. Clinical Trial.
Cytotoxic innate lymphoid cells sense cancer cell-expressed interleukin-15 to suppress human and murine malignancies.
Kansler ER, Dadi S, Krishna C, Nixon BG, Stamatiades EG, Liu M, Kuo F, Zhang J, Zhang X, Capistrano K, Blum KA, Weiss K, Kedl RM, Cui G, Ikuta K, Chan TA, Leslie CS, Hakimi AA, Li MO. Kansler ER, et al. Among authors: weiss k. Nat Immunol. 2022 Jun;23(6):904-915. doi: 10.1038/s41590-022-01213-2. Epub 2022 May 26. Nat Immunol. 2022. PMID: 35618834 Free PMC article.
Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade.
Ged Y, Sanchez A, Patil S, Knezevic A, Stein E, Petruzella S, Weiss K, Duzgol C, Chaim J, Akin O, Mourtzakis M, Paris MT, Scott J, Kuo F, Kotecha R, Hakimi AA, Lee CH, Motzer RJ, Voss MH, Furberg H. Ged Y, et al. Among authors: weiss k. Clin Cancer Res. 2022 Dec 1;28(23):5180-5189. doi: 10.1158/1078-0432.CCR-22-1389. Clin Cancer Res. 2022. PMID: 36190538 Free PMC article.
Author Correction: Cytotoxic innate lymphoid cells sense cancer cell-expressed interleukin-15 to suppress human and murine malignancies.
Kansler ER, Dadi S, Krishna C, Nixon BG, Stamatiades EG, Liu M, Kuo F, Zhang J, Zhang X, Capistrano K, Blum KA, Weiss K, Kedl RM, Cui G, Ikuta K, Chan TA, Leslie CS, Hakimi AA, Li MO. Kansler ER, et al. Among authors: weiss k. Nat Immunol. 2022 Aug;23(8):1285. doi: 10.1038/s41590-022-01264-5. Nat Immunol. 2022. PMID: 35705800 No abstract available.
Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas.
Yoo A, Tang C, Zucker M, Fitzgerald K, DiNatale RG, Rappold PM, Weiss K, Freeman B, Lee CH, Schultz N, Motzer R, Russo P, Coleman J, Reuter VE, Chen YB, Carlo MI, Gill AJ, Kotecha RR, Ari Hakimi A, Reznik E. Yoo A, et al. Among authors: weiss k. Eur Urol Focus. 2022 Sep;8(5):1278-1288. doi: 10.1016/j.euf.2021.12.002. Epub 2022 Mar 11. Eur Urol Focus. 2022. PMID: 35288096 Free PMC article.
A qualitative framework of non-selection factors for cytoreductive nephrectomy.
Silagy AW, Attalla K, Dinatale RG, Weiss KL, Weng S, Mano R, Iosepovici S, Marcon J, Reznik E, Kotecha RR, Motzer RJ, Voss MH, Coleman JA, Hakimi AA, Russo P. Silagy AW, et al. Among authors: weiss kl. World J Urol. 2021 Sep;39(9):3359-3365. doi: 10.1007/s00345-021-03650-4. Epub 2021 Mar 29. World J Urol. 2021. PMID: 33779820 Free PMC article.
The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management.
Weng S, DiNatale RG, Silagy A, Mano R, Attalla K, Kashani M, Weiss K, Benfante NE, Winer AG, Coleman JA, Reuter VE, Russo P, Reznik E, Tickoo SK, Hakimi AA. Weng S, et al. Among authors: weiss k. Eur Urol. 2021 Apr;79(4):468-477. doi: 10.1016/j.eururo.2020.09.027. Epub 2020 Oct 10. Eur Urol. 2021. PMID: 33046271 Free PMC article.
2,151 results